Endocannabinoid and Psychological Responses to Yoga in Healthy Adults

This study evaluates the acute effect of yoga on plasma levels of endocannabinoids and mood (i.e., mood disturbance, anxiety, pain) compared to one session of quiet rest. Participants completed one session of yoga and one session of quiet rest on two separate days.

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Behavioral: Yoga; Behavioral: Quiet Rest

• Study Type: Interventional
• Enrollment (Actual): 12
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Wisconsin
    • Madison, Wisconsin, United States, 53706
      • University of Wisconsin-Madison Natatorium

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 45 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• greater than or equal to 18 years old and < 45 years old and
• report being healthy.

Exclusion Criteria:

• Being pregnant or planning to become pregnant,
• currently smoking,
• having a history of light headedness or fainting during blood draws or physical activity,
• having a history of chest pain during physical activity,
• having a bone, joint, cardiac, or other medical condition that a doctor has said may be worsened by physical activity,
• taking medications for any chronic diseases such as high blood pressure or diabetes,
• responding 'Yes' to any of the seven questions on the Par-Q.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Yoga; 40 minutes of Vinyasa yoga	Behavioral: Yoga; 1 session
Placebo Comparator: Quiet Rest; 40 minutes of quiet rest	Behavioral: Quiet Rest; 1 session

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Plasma Concentration of N-arachidonoylethanolamine	Plasma concentration of anandamide, one effector of the endocannabinoid system	This will be measured 2 times during each study visit, once before the assigned study task (i.e., baseline) and once upon task completion (i.e., approx. 40 min. later)
Change in Plasma Concentration of 2-Arachidonoylglycerol (2-AG)	Plasma concentration of 2-AG, one effector of the endocannabinoid system	This will be measured 2 times during each study visit, once before the assigned study task (i.e., baseline) and once upon task completion (i.e., approx. 40 min. later)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Total Mood Disturbance as Measured by the Profile of Mood States	65-item self-reported mood questionnaire that measures mood "right now." Scores range from 0-200 with higher scores indicating higher mood disturbance.	This will be measured 2 times during each study visit, once before the assigned study task (i.e., baseline) and once upon task completion (i.e., approx. 40 min. later)
Change in State Anxiety as Measured by the State-Trait Anxiety Inventory	20-item self-reported anxiety questionnaire that measures anxiety "right now." Scores range from 20-80 with higher scores indicating higher anxiety.	This will be measured 2 times during each study visit, once before the assigned study task (i.e., baseline) and once upon task completion (i.e., approx. 40 min. later)
Change in Total Pain as Measured by the Short-form McGill Pain Questionnaire	15-item self-reported pain questionnaire that measures pain "right now." Scores range from 0-45 with higher scores indicating higher pain.	This will be measured 2 times during each study visit, once before the assigned study task (i.e., baseline) and once upon task completion (i.e., approx. 40 min. later)

Collaborators and Investigators

• Sponsor: University of Wisconsin, Madison
• Investigators: Principal Investigator: Kelli Koltyn, PhD, University of Wisconsin, Madison

Study record dates

Study Major Dates

• Study Start (Actual): December 12, 2017
• Primary Completion (Actual): May 16, 2018
• Study Completion (Actual): May 16, 2018

Study Registration Dates

• First Submitted: June 21, 2018
• First Submitted That Met QC Criteria: October 15, 2018
• First Posted (Actual): October 18, 2018

Study Record Updates

• Last Update Posted (Actual): December 8, 2020
• Last Update Submitted That Met QC Criteria: November 16, 2020
• Last Verified: November 1, 2020

More Information

Terms related to this study

• Other Study ID Numbers: 2017-0980; A176000 (Other Identifier: UW Madison); EDUC/KINESIOLOGY/KINESIO (Other Identifier: UW Madison)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No